-
CASI Pharmaceuticals Secures USD 15 Million in PIPE Transaction for Anti-CD38 Monoclonal Antibody Development
•
CASI Pharmaceuticals (NASDAQ: CASI), a biopharmaceutical company based in China, has announced the signing of agreements with several investors for a public equity financing (PIPE) transaction, securing a raise of USD 15 million. Concurrently, the company also disclosed plans to submit an Investigational New Drug (IND) filing to the U.S.…
-
CASI Pharmaceuticals Reports Q3 2023 Results with Mixed Fortunes and Positive Developments
•
China-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has unveiled its financial results for the third quarter of 2023. The company reported a 13.5% decrease in sales, amounting to USD 8.8 million. Despite this downturn, several positive developments indicate a promising outlook for the company in the near future. Revenue Generator and…
